keyword
MENU ▼
Read by QxMD icon Read
search

non-small cell lung cancer

keyword
https://www.readbyqxmd.com/read/28107536/correction-methylation-markers-of-early-stage-non-small-cell-lung-cancer
#1
Kaie Lokk, Tõnu Vooder, Raivo Kolde, Kristjan Välk, Urmo Võsa, Retlav Roosipuu, Lili Milani, Krista Fischer, Marina Koltsina, Egon Urgard, Tarmo Annilo, Andres Metspalu, Neeme Tõnisson
[This corrects the article DOI: 10.1371/journal.pone.0039813.].
2017: PloS One
https://www.readbyqxmd.com/read/28107192/incidence-and-risk-of-infections-associated-with-egfr-tkis-in-advanced-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#2
Yingtian Wang, Mingzhen Wang, Qiaoxia Wang, Zhiying Geng, Mingxiang Sun
Currently, the overall incidence and risk of infections with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) patients remained undetermined. We searched Pubmed for related articles published from 1 January 1990 to 31 November 2015. Eligible studies included prospective randomized controlled trials (RCTs) evaluating therapy with or without EGFR-TKIs in patients with NSCLC. Data on infections were extracted. Pooled incidence, Peto odds ratio (Peto OR), and 95% confidence intervals (CIs) were calculated...
January 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28107191/epidermal-growth-factor-receptor-egfr-mutations-in-non-small-cell-lung-cancer-nsclc-of-yunnan-in-southwestern-china
#3
Yongchun Zhou, Yanlong Yang, Chenggang Yang, Yunlan Chen, Changshao Yang, Yaxi Du, Guangqiang Zhao, Yinjin Guo, Lianhua Ye, Yunchao Huang
To investigate the Epidermal Growth Factor Receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) in Yunnan province in southwestern China, we detected EGFR mutation by Amplification Refractory Mutation System (ARMS) polymerase chain reaction (PCR) using DNA samples from 447 pathologically confirmed NSCLC specimens (175 tissue, 256 plasma and 16 cytologic samples). The relationship between EGFR mutations and demographic and clinical factors were further explored. Subgroup analyses according to sample type (tissue and plasma) and histological type (adenocarcinoma) were done...
January 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28106539/plasma-mir-92a-2-as-a-biomarker-for-small-cell-lung-cancer
#4
Yalan Yu, Jiangcheng Zuo, Qian Tan, Khaing Zar Thin, Ping Li, Man Zhu, Mingxia Yu, Zhenming Fu, Chunzi Liang, Jiancheng Tu
MicroRNAs (miRNAs) are small, non-coding RNAs that play important roles in the carcinogenesis and progression of cancers. Aberrant expression of miRNAs in tissue and plasma has been found in various solid tumors. Our research aims to determine whether the abnormal plasma miRNA expression patterns can be used as a predictive marker for the diagnosis and prognosis of small cell lung cancer (SCLC). Fifty SCLC patients and 30 healthy controls annotated with clinical characteristics and specific questionnaire survey for smoking history were available...
January 13, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/28105244/her2-overexpression-reverses-the-relative-resistance-of-egfr-mutant-h1975-cell-line-to-gefitinib
#5
Jing Xu, Li Shen, Bi-Cheng Zhang, Wen-Hong Xu, Shu-Qin Ruan, Chi Pan, Qi-Chun Wei
Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that has been demonstrated to be clinically useful for the treatment of patients with non-small cell lung cancer (NSCLC). However, ~50% of patients do not respond to EGFR TKI treatment through the emergence of mutations, such as T790M. Therefore, it is important to determine which patients are eligible for treatment with gefitinib. As a preferred dimerization partner for EGFR, the role of EGFR 2 (HER2) in mediating sensitivity to gefitinib is poorly understood...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28105215/role-of-axl-expression-in-non-small-cell-lung-cancer
#6
Xiaohan Qu, Jinlu Liu, Xinwen Zhong, Xi Li, Qigang Zhang
The present study aimed to investigate the expression profile of AXL in non-small cell lung cancer (NSCLC) and its clinical significance. The current study included 257 NSCLC patients, tyrosine-protein kinase receptor UFO (AXL) expression in paired lung cancer and adjacent normal lung tissues of NSCLC patients were compared by immunohistochemistry, western blot analysis and quantitative polymerase chain reaction (qPCR). These methods were used to detect the expression of the AXL gene and protein in fresh tissues from 35 patients...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28105212/emt-influences-the-expression-of-ck19-in-pleural-effusion-derived-lung-cancer-cells-and-their-invasion-and-metastasis
#7
Dongyun Huang, Wenjing Xu, Xingxiang Xu, Xudong Zhang, Rui Zhou, Ping Chen
Lung cancer is the most common cancer after breast and colon cancer, with high rates of mortality, worldwide. There are two main types of lung cancer, small cell lung carcinoma (SCLC), which accounts for approximately 20% of all lung cancer cases and non-SCLC, which accounts for almost 80% of lung cancer cases. Although lung cancer is one of the most aggressive types of cancer, progress in achieving better clinical outcomes has been gradual. Even though a number of markers have been suggested for the diagnosis of lung cancer and monitoring of disease progression, there is no clear way of assessing the invasion, epithelial-mesenchymal transition (EMT) and metastasizing capability of the primary tumor cells...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28105168/relationship-between-mir-7-expression-and-treatment-outcomes-with-gefitinib-in-non-small-cell-lung-cancer
#8
Kun Mou, Weiwei Gu, Cuihua Gu, Jinzhong Zhang, Wenjie Qwang, Gang Ren, Jing Tian
The aim of the present study was to assess the effects of gefitinib chemotherapy on the serum levels of miR-7 in patients with non-small cell lung cancer (NSCLC). A total of 126 patients were enrolled in the present study (stage I-II, n=54 and stage III-IV, n=72). Patients with stage I-II NSCLC underwent surgery in combination with gefitinib chemotherapy, whereas only gefitinib chemotherapy was administered to patients with stage III-IV disease. Serum levels of miR-7 before and after treatment were measured with quantitative polymerase chain reaction using fluorogenic probes, and miR-7 positivity and scoring in resected specimens were determined by immunohistochemistry...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28105150/ovarian-metastasis-from-non-small-cell-lung-cancer-with-alk-and-egfr-mutations-a-report-of-two-cases
#9
Rosemary T Mushi, Yumei Yang, Qian Cai, Ruiguang Zhang, Gang Wu, Xiaorong Dong
Ovarian metastasis from non-small cell lung cancer (NSCLC) is a rare condition. The current study presents the cases of 2 female patients aged 38 and 47 years old, respectively, who were initially diagnosed with NSCLC adenocarcinoma on histology. Both patients initially presented with chest pain and a cough, and subsequently developed ovarian metastases following multiple treatments. The 38-year old patient exhibited an epidermal growth factor receptor mutation, confirmed by scorpion/amplified refractory mutation system analysis from a lung biopsy...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28104619/osimertinib-benefit-in-egfr-mutant-nsclc-patients-with-t790m-mutation-detected-by-circulating-tumour-dna
#10
J Remon, C Caramella, C Jovelet, L Lacroix, A Lawson, S Smalley, K Howarth, D Gale, E Green, V Plagnol, N Rosenfeld, D Planchard, M V Bluthgen, A Gazzah, C Pannet, C Nicotra, E Auclin, J C Soria, B Besse
BACKGROUND: Approximately 50% of Epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) will acquire resistance by the T790M mutation. Osimertinib is the standard of care in this situation. The present study assesses the efficacy of osimertinib when T790M status is determined in circulating cell-free tumour DNA (ctDNA) from blood samples in progressing advanced EGFR-mutant NSCLC patients. MATERIAL AND METHODS: ctDNA T790M mutational status was assessed by Inivata InVision(TM) (eTAm-Seq(TM)) assay in 48 EGFR-mutant advanced NSCLC patients with acquired resistance to EGFR TKIs without a tissue biopsy between April 2015 and April 2016...
January 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28104581/high-glucose-stimulates-proliferation-and-inhibits-apoptosis-of-non-small-cell-lung-cancer-cells-by-jnk-mediated-downregulation-of-p53-pathway
#11
Lumei Wang, Nanzhe Zhong, Shujuan Liu, Xiaoyan Zhu, Yujian Liu
No abstract text is available yet for this article.
January 18, 2017: Acta Biochimica et Biophysica Sinica
https://www.readbyqxmd.com/read/28104536/exome-wide-association-study-identifies-low-frequency-coding-variants-in-2p23-2-and-7p11-2-associated-with-survival-of-non-small-cell-lung-cancer-patients
#12
Meng Zhu, Liguo Geng, Wei Shen, Yuzhuo Wang, Jia Liu, Yang Cheng, Cheng Wang, Juncheng Dai, Guangfu Jin, Zhibin Hu, Hongxia Ma, Hongbing Shen
INTRODUCTION: A growing body of evidence has suggested that low-frequency or rare variants might have strong effects on the development and prognosis of cancer. Here, we aim to assess the role of low-frequency and rare coding variants in the survival of non-small cell lung cancer (NSCLC) in Chinese populations. METHODS: We performed an exome-wide scan of 247,870 variants in 1,008 NSCLC patients and replicated the promising variants by using imputed genotype data of The Cancer Genome Atlas (TCGA) with a cox regression model...
January 16, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28104361/igfbp-a-novel-target-of-lung-cancer
#13
REVIEW
QiongGe Hu, Yong Zhou, Kejing Ying, Wenjing Ruan
The insulin-like growth factor-1 receptor(IGF-1R) is a central component of lung cancer signal transduction pathways. A phase III study failed for carboplatin, paclitaxel, with or without figitumumab in first-line treating metastatic non-small cell lung cancer (NSCLC). There is an urgent need for a better understanding of signaling in IGF system. Insulin-like growth factor-binding proteins(IGFBPs) function as modulators for IGF signaling through sequestration of IGFs in serum and the extracellular fluid. IGFBPs can also act as transporters or modulators for IGF action and insulin action...
January 16, 2017: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/28103976/-research-progress-of-targeted-therapy-for-anaplastic-lymphoma-kinase-and-other-rare-driver-genes-in-advanced-non-small-cell-lung-cancer
#14
Quan Zhang, Shucai Zhang
Targeted therapy was one of the major treatments in advanced non-small cell lung cancer (NSCLC) with positive driver genes. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers have also undergone deep investigation about the molecular mechanisms underlying inherent or acquired resistance to these targeted therapies. This review aimed to summarize the advanced developments of targeted therapy for anaplastic lymphoma kinase (ALK) and other rare driver genes in NSCLC...
January 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28103975/-research-progress-of-targeted-therapy-for-egfr-gene-in-non-small-cell-lung-cancer
#15
Hui Zhang, Shucai Zhang
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have brought great clinical benefit to patients with EGFR-sensitive mutations. With the deepening of clinical and basic research, EGFR-TKIs have received more and more attention. In this review, we summarize the latest research development about EGFR-targeted drugs in 2016.
January 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28103974/-phase-i-study-of-etoposide-and-cisplatin-chemotherapy-dose-escalation-%C3%A2-with-concurrent-twice-daily-radiotherapy-for-patients-%C3%A2-with-limited-stage-small-cell-lung-cancer
#16
Jing You, Huiming Yu, Maxiaowei Song, Chen Shi, Xiaohang Wang, Ye Zheng, Rong Yu, Anhui Shi, Guangying Zhu
BACKGROUND: Concurrent twice-daily radiotherapy with chemotherapy of EP regimen is one of the current standard treatments for limited-stage small cell lung cancer. However, the safely tolerated dose of standard chemotherapy for Chinese patients is not decided. This study was to evaluate the toxicity and the maximum tolerated dose (MTD) of etoposide and cisplatin concurrent with thoracic radiation therapy for patients with limited-stage small cell lung cancer. METHODS: Patients with histologically proven limited-stage small cell lung cancer (LS-SCLC) were eligible...
January 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28103971/-surgical-treatment-of-small-pulmonary-nodules-under-video-assisted-thoracoscopy-%C3%A2-a-report-of-129-cases
#17
Tong Wang, Tiansheng Yan, Feng Wan, Shaohua Ma, Keyi Wang, Jingdi Wang, Jintao Song, Wei He, Jie Bai, Liang Jin
BACKGROUND: The development of image technology has led to increasing detection of pulmonary small nodules year by year, but the determination of their nature before operation is difficult. This clinical study aimed to investigate the necessity and feasibility of surgical resection of pulmonary small nodules through a minimally invasive approach and the operational manner of non-small cell lung cancer (NSCLC). METHODS: The clinical data of 129 cases with pulmonary small nodule of 10 mm or less in diameter were retrospectively analyzed in our hospital from December 2013 to November 2016...
January 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28103968/-gene-expression-and-clinical-characteristics-of-molecular-targeted-therapy-%C3%A2-in-non-small-cell-lung-cancer-patients-in-shandong
#18
Xiuli Qiao, Dan Ai, Honglu Liang, Dianbin Mu, Qisen Guo
BACKGROUND: Molecular targeted therapy has gradually become an important treatment for lung cancer, the aim of this research is to analyze the clinicopathologic features associated with the gene mutation status of epidermal growth factor receptor (EGFR), echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) and Kirsten rat sarcoma viral oncogene (KRAS) in non-small cell lung cancer (NSCLC) patients and determine the most likely populations to benefit from molecular target therapy treatment...
January 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28103823/stepwise-addition-of-genetic-changes-correlated-with-histological-change-from-well-differentiated-to-sarcomatoid-phenotypes-a-case-report
#19
Taichiro Goto, Yosuke Hirotsu, Hitoshi Mochizuki, Takahiro Nakagomi, Toshio Oyama, Kenji Amemiya, Masao Omata
BACKGROUND: Sarcomatoid cancer is defined by the World Health Organization as a category of non-small cell lung cancers with sarcoma or sarcoma-like differentiation. They are characterized by poor prognosis and resistance to conventional chemotherapy. However, the mutational profile of sarcomatoid cancer remains yet to be elucidated. Sarcomatoid cancers are usually biphasic tumors composed of carcinomatous and sarcomatous components, but the evolutional development of sarcomatoid cancer is controversial...
January 19, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28103612/a-phase-iii-randomised-controlled-trial-of-erlotinib-vs-gefitinib-in-advanced-non-small-cell-lung-cancer-with-egfr-mutations
#20
J J Yang, Q Zhou, H H Yan, X C Zhang, H J Chen, H Y Tu, Z Wang, C R Xu, J Su, B C Wang, B Y Jiang, X Y Bai, W Z Zhong, X N Yang, Y L Wu
BACKGROUND: A phase III trial was conducted to compare the safety and efficacy of erlotinib with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations in exon 19 or 21. METHODS: Eligible patients were randomised to receive erlotinib (150 mg per day) or gefitinib (250 mg per day) orally until disease progression or unacceptable toxicity. We aimed to determine whether erlotinib is superior to gefitinib in efficacy...
January 19, 2017: British Journal of Cancer
keyword
keyword
15685
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"